Authors

• Andrew H. Wei (ORCID: https://orcid.org/0000-0002-7514-3298)
• Martin Carroll (ORCID: https://orcid.org/0000-0002-5622-3735)
• Alexander E. Perl (ORCID: https://orcid.org/0000-0002-1463-2231)
• David C.S. Huang (ORCID: https://orcid.org/0000-0002-3101-4873)
• Chong Chyn Chua (ORCID: https://orcid.org/0000-0002-2162-3288)
• Fiona C. Brown (ORCID: https://orcid.org/0000-0001-9711-9769)
• Piers A. Blombery (ORCID: https://orcid.org/0000-0002-9902-0022)
• Richard W. Birkinshaw (ORCID: https://orcid.org/0000-0003-1825-0182)
• Peter E. Czabotar (ORCID: https://orcid.org/0000-0002-2594-496X)
• Thomas Morley
• Xin Wang (ORCID: https://orcid.org/0000-0001-9827-3098)
• Salvatore F. Priore
• Giovanna Pomilio
• Guang Yang (ORCID: https://orcid.org/0000-0002-8379-7478)
• Sila Kasapgil

Institutions

• The Royal Melbourne Hospital (AU)
• Memorial Sloan Kettering Cancer Center (US)
• The University of Melbourne (AU)
• Walter and Eliza Hall Institute of Medical Research (AU)
• Hospital of the University of Pennsylvania (US)
• Peter MacCallum Cancer Centre (AU)
• Computational Diagnostics (United States) (US)
• Monash University (AU)
• University of Pennsylvania (US)

Publication Details

Journal

Blood Advances

Published

2024-10-07

DOI

https://doi.org/10.1182/bloodadvances.2024014446

Citations

11

Primary Topic

Acute Myeloid Leukemia Research

Type

article

Field-Weighted Citation Impact

5.00

Funders

• Amgen
• Bristol-Myers Squibb
• Pfizer
• AstraZeneca
• Gilead Sciences
• Veski
• Astex Pharmaceuticals
• Foghorn Therapeutics
• BeiGene
• Syndax Pharmaceuticals
• Astellas Pharma
• Servier
• Genentech
• Medical Research Council
• National Health and Medical Research Council
• Daiichi Sankyo Europe